~~<i id='9F4A3D5A4A'><strike id='9F4A3D5A4A'><tt id='9F4A3D5A4A'><pre id='9F4A3D5A4A'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：leisure time 2025-10-06 13:03:53 Page View：66989

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： STAT Virtual Event: ASCO Recap, Live!
Next article： Sports medicine is finally prioritizing gender equality

focus

Tori Bowie and the unacceptable rates of Black maternal death

AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

Moderna says combo Covid

AlexHogan/STATModernaannouncedMondaythat,inaPhase3clinicaltrial,itscombinationCovid-19andinfluenzava

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Louisiana bill approved classifying abortion pills as controlled substances

AllenG.Breed/APBATONROUGE—Twoabortion-inducingdrugscouldsoonbereclassifiedascontrolledanddangeroussu